Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%
Corroborated by 2 sources from 2 publishers
TL;DR
Reports differ across sources; according to finance.yahoo.com, harold Bernstein, President, R&D & CMO of Maze Therapeutics (NASDAQ:MAZE), reported the exercise of 15,000 stock options and immediate sale of the corresponding common shares for a total value of approximately $736,000 according to the SEC Form 4 filing.
Sources
1
Investing.com News
https://www.investing.com/news/earnings/maze-therapeutics-stock-soars-22-on-positive-trial-data-for-mze829-93CH-4579653
2
Investing.com News
https://www.investing.com/news/analyst-ratings/maze-therapeutics-stock-rating-held-at-buy-by-td-cowen-on-trial-data-93CH-4580557
3
Investing.com News
https://www.investing.com/news/analyst-ratings/btig-reiterates-maze-therapeutics-stock-rating-on-trial-results-93CH-4580560
4
Yahoo Finance News
https://finance.yahoo.com/markets/stocks/articles/maze-insider-reports-736k-sale-190104645.html